e-Drug3D

2065

RITLECITINIB

INN
RITLECITINIB

cas 1792180-81-4

CLASS

ANTINEOPLASTIC
JANUS KINASE 3 (JAK3) KINASE INHIBITOR
TREATMENT OF SEVERE ALOPECIA AREATA IN ADULTS AND ADOLESCENTS 12 YEARS AND OLDER

ROUTE (list)

ORAL

ATC code

L04AF08

PK parameters

F 64 PERCENT
Tmax 1 HOUR
PPB 14 PERCENT
t1/2 1.8 HOUR

Solubility

FREELY SOLUBLE IN WATER

Target

TARGET JANUS KINASE 3 (JAK3)

Tyrosine-protein kinase JAK3 UNIPROT P52333

Download SDF file

2-Propen-1-one, 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]- (ACI)

Formula:
C15H19N5O

Calculated chemical properties:

MW 285.35
NB_atoms 21
XLogP 1.94
PSA 58.92
NB_HD 2
NB_HA 6
fsp3 0.40
Lipinski(0=no;1=yes) 1

FDA
NDA 215830 (pdf not found) INN (RITLECITINIB TOSYLATE) LITFULO (PFIZER) APPROVAL= AP YEAR= 2023 NEWMOLECULARENTITY